2seventy Bio’s Phase I trial of its acute myeloid leukemia CAR-T candidate, SC-DARIC33, in children and young adults has been halted by the US Food and Drug Administration following the death of one of the participants.
CAR-T Clinical Hold Adds To 2Seventy’s Headwinds
Abecma Revenues Set To Decline In Q3
An early stage CAR-T trial in acute myeloid leukemia has been halted after a patient death, adding to 2Seventy’s difficulties in growing sales of its myeloma treatment Abecma.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.